hubXchange returns with its latest series of roundtables!

hubXchange returns with its latest series of roundtables!Mike.HammertonTue, 17/12/2024 - 11:35Bookmark this

featured-image

hubXchange invites you to participate in its highly-anticipated San Diego Series 2025, a series of focused, high-level roundtable events designed to address key challenges and innovations across the life sciences industry. Taking place in the vibrant city of San Diego, this series is the ultimate platform for scientific leaders and executives to exchange ideas, foster collaborations, and drive progress in transformative therapies and cutting-edge technologies. What Makes hubXchange’s Roundtable Series Unique? San Deigo Event Series Details Dates: February 19, 20, 24, 25, 2025 Location: San Diego, CA Antibody Therapeutics Xchange | 19th Feb, 2025 Discussion topics; Antibody Drug Conjugates, Lead Identification & Optimization, Formats & Scaffolds, and Bi/Multispecifics.

To find out more & register online: https://bit.ly/41Hd97P Immunotherapies Xchange | 20th Feb, 2025 Discussion topics; Immunogenicity, Translational Immunology, Clinical Development, and Immune Regulation. To find out more & register online: https://bit.



ly/3ZUUK5R AI in Drug Discovery Xchange | 24th Feb, 2025 Discussion topics; Data Quality, Target Identification, Lead Generation & Optimization, and Drug Response Prediction. To find out more & register online: https://bit.ly/4gx5rkw Advanced Therapies Xchange | 25th Feb, 2025 Discussion topics; Cell Therapy Development, Gene Therapy Development, C & G Bioprocessing, C & G Manufacturing.

To find out more & register online: https://bit.ly/3OZNcJ4 By attending the hubXchange San Diego Roundtable Event/s, you will gain exclusive insights into the latest trends and innovations shaping the future of advanced therapies, antibody therapeutics, immunotherapies, and AI-driven drug discovery. Each session is tailored to facilitate meaningful dialogue, idea exchange, and actionable solutions for your most pressing challenges.

Senior Scientists and above, from Bio and Pharma companies with a drug pipeline..